How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comMulticentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy
Description:
This trial is comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine administration versus decision of radioiodine treatment guided by a post-operative work-up based on serum Tg values and diagnostic RAI scintigraphy
Sponsor:
Centre Francois Baclesse
Phase:
Phase 3
Contacts:
Stéphane BARDET, MDs.bardet@baclesse.unicancer.fr
(33)231455050
Government Study Link:
NCT04290663 - Click here to see study onClinicalTrials.gov
Isotope(s):
IODINE-131
Radioisotope: I-131
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 8 Days
Decay Mode: BETA, GAMMA
Energy: βeta max 0.6 MeV Gamma 364 keV
Range: In Tissue: 0.8 -2.1 mm
Decay Daughters: Xe131
Status: FDA Approval: 1951-First FDA Approved Radiopharmaceutical), AZEDRA® (2018)
Target(s):
Share your feedback
Help us improve your experience